Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 433 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Cancer Patients Have Been Lonelier During the COVID-19 Pandemic May 27, 2021 Cuando necesita ayuda con responsabilidades de cuidado June 15, 2021 Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities October 22, 2021 ESMO Breast Cancer Congress 2022 April 20, 2022 Load more HOT NEWS ¿Puede el uso de un microondas causar cáncer? Young Mom-of-Three Learns She Has Stage 4 Breast Cancer, 5 Days... Nivolumab: Μία σημαντική θεραπευτική επιλογή As More People with Cancer Use Medical Cannabis, Oncologists Face Questions...
